In the two years since Ideaya Biosciences Inc. closed its $40 million series A, the South San Francisco-based company has grown from two to 42 employees, identified lead programs in synthetic lethality and immunotherapy, prepared to file three INDs in the next 12 to 18 months and positioned itself to move multiple candidates into the clinic by the end of 2019. That trajectory was more than sufficient to attract $94 million in a series B financing that will see the company into the second half of 2021, according to CEO Yujiro S. Hata.